Scientific Program (All times are CET)

Click on the session title that has an icon next to it to view the on-demand recording

Thursday, May 14, 2020

11:15–11:30 Welcome address by congress co-chairs
Thierry Facon, France; Mohamad Mohty, France; Arnon Nagler, Israel
11:30–13:30 Session 1: Update on disease biology
Disease risk scoring
Jill Corre, France
Genomics of high risk myeloma
Nikhil Munshi, USA
Biology of bone disease
Evangelos Terpos, Greece
IMiDs resistance pathways
Keith Stewart, USA
MRD as a tool to discontinue therapy?
Luciano Costa, USA
Technical break
13:45–14:45 Sponsored Satellite symposium GSK
14:45–16:05 Session 2: Immunotherapy: where do we stand?
Role of the microenvironment
Irene Ghobrial, USA
[Not available on-demand] Immune status in myeloma
Gordon Cook, UK
[Not available on-demand] Strategies to reverse immune deregulation in myeloma
Paola Neri, Canada
16:05–16:55 Session 3: Therapeutic development in myeloma
[Not available on-demand] Exploiting signaling pathways
Marc Raab, Germany
Cellular therapy: NK cells as a model
Michael O’Dwyer, Ireland
16:55–17:35 Session 4: Special lectures
Waldenstrom macroglobulinemia: state of the art
Jorge Castillo, USA
17:35–18:05 Session 5: Keynote lecture
[Not available on-demand] Immunotherapy of myeloma: past, present and future
Herman Einsele, Germany
18:05-19:05 Q&A Session

Friday, May 15, 2020

08:00–10:00 Session 6: Disease evaluation and monitoring
Myeloma diagnostic criteria: the complex situations
Shaji Kumar, USA
[Not available on-demand] MRD monitoring: when, how and in which patient?
Bruno Paiva, Spain
MGUS diagnosis: a step by step approach
Graham Jackson, UK
Imaging: the essential work-up
Elena Zamagni, Italy
Q&A session 
10:00–11:15 Session 7: Hot debates
Management of elderly myeloma:

Proteasome inhibitors-based therapy
María-Victoria Mateos, Spain

Treatment of smoldering myeloma:

Ready for prime time
Vincent Rajkumar, USA

Not yet: more data are needed
Xavier Leleu, France

11:15–12:15 Session 8: Management of young myeloma
Novel induction regimens prior to transplant
Philippe Moreau, France
[Not available on-demand] Role of consolidation (beside a second auto)
Peter Sonneveld, The Netherlands
Maintenance therapy is mandatory after auto-transplant
Phil McCarthy, USA
12:15–13:25 Session 9: Hot debates
Transplant for all eligible patients:

– Yes: Arnon Nagler, Israel

– No: Sagar Lonial, USA

Anti-CD38 antibodies-based induction prior to transplant for all:

– No: Francesca Gay, Italy

– Yes: Mohamad Mohty, France

13:25–15:25 Session 10: Optimizing myeloma therapy
[Not available on-demand] Frailty assessment
Alessandra Laroca, Italy
[Not available on-demand] Improving supportive care
Heinz Ludwig, Austria
Practical considerations when using anti-CD38 antibodies
Torben Plesner, Denmark
Management of cardiovascular adverse events
Inger Nijhof, The Netherlands
15:25–16:30 Session 11: Special lectures
[Not available on-demand] How to cure a myeloma patient frontline?
Jesus San Miguel, Spain
How to extend survival at relapse?
Meletios-Athanasios Dimopoulous, Greece
16:30–17:45 Session 12: Oral Abstracts 
A PHASE 1B/2 STUDY OF JNJ-4528, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY TARGETING B-CELL MATURATION ANTIGEN (BCMA), IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS FROM CARTITUDE-1
DREAMM-2 PIVOTAL STUDY PRIMARY ANALYSIS: SINGLE-AGENT BELANTAMAB MAFODOTIN (GSK2857916) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO PROTEASOME INHIBITORS (PIS), IMMUNOMODULATORY AGENTS, AND REFRACTORY AND/OR INTOLERANT TO ANTI-CD38 MONOCLONAL ANTIBODIES (MABS)
DREAMM-5: PLATFORM TRIAL EVALUATING BELANTAMAB MAFODOTIN (A BCMA-DIRECTED IMMUNO-CONJUGATE) IN COMBINATION WITH NOVEL AGENTS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
FINAL ANALYSIS OF A PHASE I-b STUDY OF ISATUXIMAB COMBINED WITH CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): (NCT-02332850)
OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE REMAIN COMPARABLE TO THE OUTCOMES REPORTED IN THE PHASE 3 TOURMALINE-MM1 STUDY
17:45-18:45 Q&A Session

Saturday, May 16, 2020

08:00–10:30 Session 13: Snapshot results of novel drugs in the relapsed/refractory myeloma
  [Not available on-demand] Proteasome inhibitors
Michel Delforge, Belgium
  IMiDs
Enrique Ocio, Spain
  [Not available on-demand] Bite antibodies
Herman Einsele, Germany
  Targeting SLAMF7
Katia Weisel, Germany
  Novel alkylating agents
Paul Richardson, USA
  Targeting CD38
Tom Martin, USA
  [Not available on-demand] Antibody drug conjugates
Suzan Trudel, Canada
10:30–12:05 Session 14: The challenging cases forum
  Primary refractory young myeloma
Salomon Manier, France
  Frontline therapy under dialysis (elderly patient)
Paula Rodriguez Otero, Spain
  How to manage myeloma patients during a pandemic?
Meral Beksac, Turkey
  Plasma cell leukemia – what is new in 2020?
Artur Jurczyszyn, Poland
11:50-12:05 Technical Break
12:05–13:35 Satellite symposium Adaptive Biotechnologies®
The relevance of MRD assessment in the clinical management of Multiple Myeloma (MM) patients

 

An overview of sequence-based immune receptor profiling
Lanny Kirsch, USA

 

The relevance of depth of response and sustained MRD negativity in MM
Bruno Paiva, Spain

 

Managing MM in real-world practice: How can MRD inform treatment decisions
Karthik Ramasamy, UK
13:35–14:30 Session 15: Future research/perspectives in myeloma
  [Not available on-demand] EMN
Roman Hajek, Czech Republic
  The patients’ perspective in clinical trials
Rafat Abonour, USA
  [Not available on-demand] UK
Kwee Yong, UK
14:30–15:20 Session 16: Special lectures
  Optimal choice of therapy in first relapse
Jean-Luc Harousseau, France
  Optimal choice of therapy beyond first relapse
Saad Usmani, USA
15:20–16:30 Session 17: Hot debates
  MRD as an endpoint for frontline therapy?
  [Not available on-demand] – Yes: Charlotte Pawlyn, UK
  – No: Deepu Madduri, USA
  Continuous therapy in elderly myeloma?
  – Yes: Nizar Bahlis, Canada
  [Not available on-demand] – No: Suzanne Lentzsch, USA
16:30–17:05 Session 18: Closing lecture
  The next steps toward cure
Kenneth Anderson, USA
17:05–18:05 Q&A Session